# Phase II Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer Patients

> **NCT00714376** · PHASE2 · TERMINATED · sponsor: **CHU de Quebec-Universite Laval** · enrollment: 6 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00714376
- **Lead sponsor:** CHU de Quebec-Universite Laval
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-05
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Prematurely terminated due to financial considerations
- **Last updated:** 2012-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00714376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00714376, "Phase II Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00714376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*